In this study, we employed an established model of T2DM and obesity (ob/ob mouse) to explore the involvement of the MGO-AGE-RAGE axis in DBD, focusing on the ability of the RAGE inhibitor TTP488 (azeliragon) to reduce the functional and molecular alterations observed in the bladder tissues. This evidence concerns the gene RENBP and type 2 diabetes mellitus.